A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

NCT00920647 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Hunter Syndrome

Interventions

OTHER: Control
DRUG: Idursulfase IT (1 mg)
DRUG: Idursulfase IT (10 mg)
DRUG: Idursulfase IT (30 mg)

Sponsor

Shire